Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorShitara, Kohei
dc.contributor.authorDoi, Toshihiko
dc.contributor.authorHosaka, Hisashi
dc.contributor.authorThuss-Patience, Peter
dc.contributor.authorSantoro, Armando
dc.contributor.authorLongo-Muñoz, Federico
dc.contributor.authorAlsina Maqueda, Maria
dc.date.accessioned2022-09-09T07:12:40Z
dc.date.available2022-09-09T07:12:40Z
dc.date.issued2022-05
dc.identifier.citationShitara K, Doi T, Hosaka H, Thuss-Patience P, Santoro A, Longo F, et al. Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS). Gastric Cancer. 2022 May;25:586–97.
dc.identifier.issn1436-3305
dc.identifier.urihttp://hdl.handle.net/11351/8082
dc.descriptionAge groups; Gastrointestinal neoplasms; Trifluridine
dc.description.abstractBackground Trifluridine and tipiracil (FTD/TPI) demonstrated survival benefit vs placebo and manageable safety in previously treated patients with metastatic gastric/gastroesophageal junction cancer (mGC/GEJC) in the randomized, placebo-controlled, phase 3 TAGS study. This subgroup analysis of TAGS examined efficacy/safety outcomes by age. Methods In TAGS, patients with mGC/GEJC and ≥ 2 prior therapies were randomized (2:1) to receive FTD/TPI 35 mg/m2 or placebo, plus best supportive care. A preplanned subgroup analysis was performed to evaluate efficacy and safety outcomes in patients aged < 65, ≥ 65, and ≥ 75 years. Results Among 507 randomized patients (n = 337 FTD/TPI; n = 170 placebo), 55%, 45%, and 14% were aged < 65, ≥ 65, and ≥ 75 years, respectively. Overall survival hazard ratios for FTD/TPI vs placebo were 0.67 (95% CI 0.51–0.89), 0.73 (95% CI 0.52–1.02), and 0.67 (95% CI 0.33–1.37) in patients aged < 65, ≥ 65, and ≥ 75 years, respectively. Regardless of age, patients receiving FTD/TPI experienced improved progression-free survival and stayed longer on treatment than those receiving placebo. Among FTD/TPI-treated patients, frequencies of any-cause grade ≥ 3 adverse events (AEs) were similar across age subgroups (80% each), although grade ≥ 3 neutropenia was more frequent in older patients [40% (≥ 65 and ≥ 75 years); 29% (< 65 years)]; AE-related discontinuation rates did not increase with age [14% (< 65 years), 12% (≥ 65 years), and 12% (≥ 75 years)]. Conclusions The results of this subgroup analysis show the efficacy and tolerability of FTD/TPI treatment regardless of age in patients with mGC/GEJC who had received 2 or more prior treatments.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesGastric Cancer;25
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectEsòfag - Càncer - Tractament
dc.subjectQuimioteràpia combinada
dc.subject.meshEsophageal Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.titleEfficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s10120-021-01271-9
dc.subject.decsneoplasias del esófago
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.relation.publishversionhttps://doi.org/10.1007/s10120-021-01271-9
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Shitara K, Doi T] Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa-shi, Japan. [Hosaka H] Department of Gastroenterology, Gunma Prefectural Cancer Center, Ota, Gunma, Japan. [Thuss-Patience P] Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Charité-Universitätsmedizin Berlin, Berlin, Germany. [Santoro A] Department of Biomedical Sciences, Humanitas University, Milan, Italy. IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy. [Longo F] Medical Oncology, Hospital Universitario Ramon y Cajal, IRYCIS, CIBERONC, Madrid, Spain. [Alsina M] Servei d’Oncologia Mèdica, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid34997449
dc.identifier.wos000740186000001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record